{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:44:49Z","timestamp":1783723489149,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008899","name":"University of South Carolina","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.bmcl.2020.127723","type":"journal-article","created":{"date-parts":[[2020,11,26]],"date-time":"2020-11-26T02:18:05Z","timestamp":1606357085000},"page":"127723","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Design, synthesis, and evaluation of substrate \u2013 analogue inhibitors of Trypanosoma cruzi ribose 5-phosphate isomerase type B"],"prefix":"10.1016","volume":"32","author":[{"given":"Soledad Natalia","family":"Gonzalez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J.","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante","family":"Maugeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Olaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breana L.","family":"Laguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Enders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Sherman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua G.","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Cazzulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward L.","family":"D'Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2020.127723_b0005","unstructured":"World Health Organization, Media Centre Fact Sheets Homepage. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/chagas-disease-(american-trypanosomiasis). Updated 2019 (accessed Jan, 2019)."},{"key":"10.1016\/j.bmcl.2020.127723_b0010","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1582-4934.2010.01007.x","article-title":"Chagas\u2019 disease: an update on immune mechanisms and therapeutic strategies","volume":"14","author":"Boscardin","year":"2010","journal-title":"J Cell Mol Med"},{"key":"10.1016\/j.bmcl.2020.127723_b0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/157489107779561625","article-title":"An insight on targets and patented drugs for chemotherapy of Chagas disease","volume":"2","author":"Duschak","year":"2007","journal-title":"Recent Pat Anti-Infect Drug Discovery"},{"key":"10.1016\/j.bmcl.2020.127723_b0020","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1191\/0960327106het653oa","article-title":"Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis)","volume":"25","author":"Castro","year":"2006","journal-title":"Hum Exp Toxicol"},{"key":"10.1016\/j.bmcl.2020.127723_b0025","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1586\/14787210.7.2.157","article-title":"Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities, Expert Rev","volume":"7","author":"Viotti","year":"2009","journal-title":"Anti-Infect Ther"},{"key":"10.1016\/j.bmcl.2020.127723_b0030","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0166-6851(98)00037-1","article-title":"Molecular characterization of susceptible and naturally resistant strains of Trypanosoma cruzi to benznidazole and nifurtimox","volume":"93","author":"Murta","year":"1998","journal-title":"Mol Biochem Parasitol"},{"key":"10.1016\/j.bmcl.2020.127723_b0035","doi-asserted-by":"crossref","first-page":"5022","DOI":"10.1073\/pnas.0711014105","article-title":"A mechanism for cross-resistance to nifurtimox and benznidazole in trypanosomes","volume":"105","author":"Wilkinson","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.bmcl.2020.127723_b0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0169-4758(96)10075-2","article-title":"The pentose phosphate pathway and parasitic protozoa","volume":"13","author":"Barrett","year":"1997","journal-title":"Parasitol. Today"},{"key":"10.1016\/j.bmcl.2020.127723_b0045","first-page":"117","article-title":"The pentose phosphate pathway in Trypanosoma cruzi, FEMS Microbiol","volume":"234","author":"Maugeri","year":"2004","journal-title":"Lett."},{"key":"10.1016\/j.bmcl.2020.127723_b0050","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1186\/1471-2164-11-610","article-title":"Structural modelling and comparative analysis of homologous, analogous and specific proteins from Trypanosoma cruzi versus Homo sapiens: putative drug targets for Chagas' disease treatment","volume":"11","author":"Capriles","year":"2010","journal-title":"BMC Genomics"},{"key":"10.1016\/j.bmcl.2020.127723_b0055","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1126\/science.1143837","article-title":"Genomic minimalism in the early diverging intestinal parasite Giardia lamblia","volume":"317","author":"Morrison","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.bmcl.2020.127723_b0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/0014-5793(71)80202-8","article-title":"The regulation of ribose-5-phosphate isomerisation in Escherichia coli K12","volume":"12","author":"Skinner","year":"1971","journal-title":"FEBS Lett"},{"key":"10.1016\/j.bmcl.2020.127723_b0065","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1128\/jb.178.4.1003-1011.1996","article-title":"Ribose catabolism of Escherichia coli: characterization of the rpiB gene encoding ribose phosphate isomerase B and of the rpiR gene, which is involved in regulation of rpiB expression","volume":"178","author":"S\u00f8rensen","year":"1996","journal-title":"J Bacteriol"},{"key":"10.1016\/j.bmcl.2020.127723_b0070","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1007\/s002940050149","article-title":"Cloning and characterization of the first two genes of the non-oxidative part of the Saccharomyces cerevisiae pentose-phosphate pathway","volume":"30","author":"Miosga","year":"1996","journal-title":"Curr Genet"},{"key":"10.1016\/j.bmcl.2020.127723_b0075","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep26937","article-title":"Disclosing the essentiality of ribose-5-phosphate isomerase B in trypanosomatids","volume":"6","author":"Faria","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2020.127723_b0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003430","article-title":"Ribose 5-phosphate isomerase B knockdown compromises Trypanosoma brucei bloodstream form infectivity","volume":"9","author":"Loureiro","year":"2015","journal-title":"PLoS Neglected Trop. Dis."},{"key":"10.1016\/j.bmcl.2020.127723_b0085","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1042\/BJ20061049","article-title":"Ribose 5-phosphate isomerase type B from Trypanosoma cruzi: kinetic properties and site-directed mutagenesis reveal information about the reaction mechanism","volume":"401","author":"Stern","year":"2007","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2020.127723_b0090","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1377\/hlthaff.25.2.420","article-title":"Estimating the cost of new drug development: is it really 802 million dollars?","volume":"25","author":"Adams","year":"2006","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.bmcl.2020.127723_b0095","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.drudis.2009.04.006","article-title":"Homology modeling in drug discovery: current trends and applications","volume":"14","author":"Cavasotto","year":"2009","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.bmcl.2020.127723_b0100","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1016\/S0021-9258(18)50493-2","article-title":"Inhibition of ribose-5-phosphate 4-phosphoerythronate isomerase","volume":"254","author":"Woodruff","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bmcl.2020.127723_b0105","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.tetlet.2003.11.038","article-title":"Synthesis and evaluation of new 4-phospho-D-erythronic acid derivatives as competitive inhibitors of spinach ribose-5-phosphate isomerase","volume":"45","author":"Burgos","year":"2004","journal-title":"Tetrahedron Lett"},{"key":"10.1016\/j.bmcl.2020.127723_b0110","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1742-4658.2010.07999.x","article-title":"Structures of type B ribose 5-phosphate isomerase from Trypanosoma cruzi shed light on the determinants of sugar specificity in the structural family","volume":"278","author":"Stern","year":"2011","journal-title":"FEBS J"},{"key":"10.1016\/j.bmcl.2020.127723_b0115","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/bj1370143","article-title":"A simple graphical method for determining the inhibition constants of mixed, uncompetitive and non-competitive inhibitors","volume":"137","author":"Cornish-Bowden","year":"1974","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2020.127723_b0120","first-page":"144","article-title":"The effect of amphotericin B on Trypanosoma cruzi in vitro and in vivo","volume":"77","author":"Horvath","year":"1974","journal-title":"J. Trop. Med. Hyg."},{"key":"10.1016\/j.bmcl.2020.127723_b0125","doi-asserted-by":"crossref","unstructured":"Sinatti, V. d. V. C., Baptista, L. P. R., Alves-Ferreira, M., Dardenne, L., Silva, J. H. M., and Guimar\u00e3es, A. C. (2017) In silico identification of inhibitors of ribose 5-phosphate isomerase from Trypanosoma cruzi using ligand and structure based approaches, J. Mol. Graphics Modell. 77, 168-180.","DOI":"10.1016\/j.jmgm.2017.08.007"},{"key":"10.1016\/j.bmcl.2020.127723_b0130","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1017\/S0031182013000292","article-title":"Novel amidines and analogues as promising agents against intracellular parasites: a systematic review","volume":"140","author":"Soeiro","year":"2013","journal-title":"Parasitology"},{"key":"10.1016\/j.bmcl.2020.127723_b0135","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1590\/0074-0276140156","article-title":"Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity","volume":"109","author":"Zingales","year":"2014","journal-title":"Mem. Inst. Oswaldo Cruz"},{"key":"10.1016\/j.bmcl.2020.127723_b0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2009\/463575","article-title":"Genotoxicity revaluation of three commercial nitroheterocyclic drugs: nifurtimox, benznidazole, and metronidazole","volume":"2009","author":"Buschini","year":"2009","journal-title":"J. Parasitol. Res."},{"issue":"e190017","key":"10.1016\/j.bmcl.2020.127723_b0145","first-page":"1","article-title":"In vitro genotoxicity of nitroimidazoles as a tool in the search of new trypanocidal agents","volume":"114","author":"Von Trompowsky","year":"2019","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bmcl.2020.127723_b0150","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1590\/0074-02760140248","article-title":"Studies of genotoxicity and mutagenicity of nitroimidazoles: demystifying this critical relationship with the nitro group","volume":"110","author":"Boechat","year":"2015","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"10.1016\/j.bmcl.2020.127723_b0155","doi-asserted-by":"crossref","first-page":"W441","DOI":"10.1093\/nar\/gkp253","article-title":"IC50-to-Ki: a web-based tool for converting IC50 to Ki values for inhibitors of enzyme activity and ligand binding","volume":"37","author":"Cer","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.bmcl.2020.127723_b0160","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1124\/dmd.115.066597","article-title":"The reliability of estimating Ki values for direct, reversible inhibition of cytochrome P450 enzymes from corresponding IC50 values: a retrospective analysis of 343 experiments","volume":"43","author":"Haupt","year":"2015","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bmcl.2020.127723_b0165","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/cmdc.200700040","article-title":"Synthesis and biological evaluation of phosphate prodrugs of 4-phospho-D-erythronohydroxamic acid, an inhibitor of 6-phosphogluconate dehydrogenase","volume":"2","author":"Ruda","year":"2007","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2020.127723_b0170","doi-asserted-by":"crossref","first-page":"6071","DOI":"10.1021\/jm1004754","article-title":"Aryl phosphoramidates of 5-phospho erythronohydroxamic acid, a new class of potent trypanocidal compounds","volume":"53","author":"Ruda","year":"2010","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20308349?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X20308349?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:37:49Z","timestamp":1760773069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X20308349"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":34,"alternative-id":["S0960894X20308349"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127723","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis, and evaluation of substrate \u2013 analogue inhibitors of Trypanosoma cruzi ribose 5-phosphate isomerase type B","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2020.127723","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"127723"}}